INTRODUCTION Many patients with inherited or acquired benign hematological disorders are at increased risk of developing severe complications from COVID-19 . These patients, therefore, require specific advice regarding isolation and changes to their usual treatment schedules . Their disease can also be associated with significant burden, and they necessitate life-long and regular access to therapy, and regular follow-up consultations and hospital visits . The current COVID-19 pandemic is therefore presenting many challenges for these patients, their families, and health-care professionals . AREAS COVERED This review provides an overview of the reported COVID-19 cases in the literature in patients with certain benign hematological disorders including thalassemia, sickle cell disease, hemophilia, immune thrombocytopenia, venous thromboembolism, and aplastic anemia . The review also outlines some recommendations on how to manage these patients if they are infected with SARS-CoV-2 . To review the literature on benign hematological disorders and COVID-19, a bibliographic search was performed using PubMed for articles published between January 2020 and June 2020 . EXPERT OPINION International efforts must be made to continue reporting and better understanding the effects of SARS-CoV-2 infection in these patients and accordingly develop a set of recommendations to optimize the treatment of future infected patients.